AJCP / Meeting AbstrActs technologists tasked with running the assay. The benefits and value of building a custom LIMS is no doubt appealing, but the challenges and risks faced while accomplishing that goal proved to be a difficult endeavor. Our clinical genomics laboratory was granted the opportunity to construct a custom LIMS to be utilized for whole exome sequencing workflows. With careful consideration of the cost and time required to develop a custom software tool that needs to mimic our current procedures, our team quickly set forth to develop a project plan. Unlike many "out of the box" systems, our development would require specific insight and technical configurations. Our team arranged workshops with both laboratory technicians and software developers to gather user requirements. We vigilantly managed time as to not disrupt ongoing clinical work. Ultimately, despite setbacks and pivots, we accomplished our mission. Due to intense project planning, multi-team communication, a clear vision, and, most importantly, user input, we created and implemented a robust automated LIMS without disrupting our clinical workflow. At the conclusion of this project, much was learned. It is critical to avoid "scope-creep" (the tendency for project goals to grow beyond the original vision). For the sake of time, implement a minimal viable product, test it, release it, and then iterate on later versions. Budget for both cost and personnel bandwidth. Understand risks, and be resourceful enough to adapt to changing goals.
Introduction: Personalized medicine is rapidly on its way to becoming the standard for patient care, especially in the area of cancer diseases. By tailoring treatments to an individual's genetic makeup, the best options can be provided for cures and management. The Jackson Laboratory for Genomic Medicine (JGM) offers the ActionSeq Plus test, which combines two Clinical Laboratory Improvement Amendments-validated assays to examine solid tumors for SNPs, micro-indels, CNVs, and gene fusions. Materials and Methods: JGM evaluated and validated its ActionSeq Plus offering for somatic mutation analysis of formalin-fixed paraffin-embedded solid tumor specimens, for its analytical sensitivity and clinical utility. ActionSeq Plus is a custom-designed targeted-capture cancer gene panel consisting of 212 genes over 4,812 coding exons, and 53 fusions over more than 285 exons. Employing an in-house proprietary bioinformatics pipeline and an extensively curated clinical knowledgebase for reporting, ActionSeq Plus provides information on active clinical trials and possible therapeutic options based on detected variants. Results: JGM has utilized this clinical test system for observational studies and live patients, and continues to evaluate and optimize the assays to provide the most efficient and useful offerings. For over 100 cases (clinical, PDX, and research) evaluated using ActionSeq Plus, an average of four variants has been identified per specimen, which are then detailed in a comprehensive report. Conclusions: By offering a clinically validated test menu, which examines solid tumor specimens through a combination of assays, JGM is able to provide physicians with a comprehensive report of the mutational variants related to a patient's cancer diagnosis. ActionSeq Plus provides a deeper, more precise understanding of the genomic instability associated with cancers, allowing for personalized targeted drug treatments. This personalized medicine approach may help to provide the patient with the most effective treatment available and provide a better quality of life.
Genetic Screening of Cystic Fibrosis Transmembrane Regulator (CFTR) in 3,746 Infertile Candidate Couples for Assisted Reproductive Techniques
Mauro Rongioletti, MD, Fabrizio Papa, Bernadetta Majolini, Cinzia Vaccarella, MD, Stefania Mariani, Domenico Bizzoco, Rosanna Squitti; Fatebenefratelli Hospital, Isola Tiberina, Rome, Italy Background: Infertility affects about 15% of couples in Italy. Cystic fibrosis transmembrane conductance regulator (CFTR) is the gene causing the most common autosomal recessive disease in Caucasians, affecting one in 2,550 live birds. Men affected are usually infertile and asymptomatic heterozygote. The prevalence of the asymptomatic heterozygote is one to 27 individuals in Italy. The 5T allele in intron 8 (IVS8-poliT) of the CFTR gene produce an abnormally low levels of the CFTR protein, since it is associated with a higher proportion of mRNA transcripts lacking exon 9, with respect to the other two alleles 7T and 9T. Aim: To report results of a routine genetic screening and prevalence of CFTR mutations and 5T allele in a population of infertile patients who were candidates for assisted reproduction technique (ART) in the hospital San Giovanni Calibita, Fatebenefratelli, Isola Tiberina, Rome, Italy. Methods: A total of 3,746 couples and an additional 357 individuals referring to the Fatebenefratelli Hospital were analyzed through the CFTR INNO-LiPA Amplification
